Search

Date 2017 Author/Creator Perini, Rodolfo F

1. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Issue 11 (November 2017)

Authors:
Balar, Arjun V; Castellano, Daniel; O'Donnell, Peter H; Grivas, Petros; Vuky, Jacqueline; Powles, Thomas; Plimack, Elizabeth R; Hahn, Noah M; de Wit, Ronald; Pang, Lei; Savage, Mary J; Perini, Rodolfo F; Keefe, Stephen M; Bajorin, Dean; Bellmunt, Joaquim
Journal:
Lancet oncology
Issue:
Volume 18:Issue 11(2017:Nov.)
Page Start:
1483
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Issue 2 (February 2017)

Authors:
Plimack, Elizabeth R; Bellmunt, Joaquim; Gupta, Shilpa; Berger, Raanan; Chow, Laura Q M; Juco, Jonathan; Lunceford, Jared; Saraf, Sanatan; Perini, Rodolfo F; O'Donnell, Peter H
Journal:
Lancet oncology
Issue:
Volume 18:Issue 2(2017:Feb.)
Page Start:
212
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search